The clock–cancer connection in prostate cancer and circadian-related therapies provide a potential novel opportunity to mitigate racial disparities in prostate cancer risk, progression, and treatment outcomes through the optimization of current treatment modalities and reduction in therapeutic resistance. The gene discussed is CLOCK; the disease is Familial prostate cancer.